Companies · Biotech / Pharma

Spinnaker Biosciences, Inc.

SOLANA BEACH · Biotech / Pharma · refined from filed group “Other Health Care

Diligence memoA one-page analyst read on Spinnaker Biosciences, Inc. — recommendation, valuation, rhythm, risks.
$2.6M
Total raised · real
3
Rounds
0.7×
Latest step-up
Top 60%
Sector rank · raised
Pre-Seed
Latest stage · inferred · Tue Nov 26 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Spinnaker Biosciences, Inc. looks fair against its niche peers and is active on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech/pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 1.13× the median modeled value of Pre-Seed Biotech / Pharma companies in 2022–2024 (28 peers) — value vs value, same stage and era.
  • Within the normal band (113% of peer median) for its niche.
Active
  • Last raise 19 mo ago; this sector typically re-raises about every 15 months.
  • Raising on or ahead of the sector's normal rhythm.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotech / Pharma

Spinnaker Biosciences, Inc. is one of 227 Biotech / Pharma companies tracked from SOLANA BEACH. By capital raised it ranks mid-pack (ahead of 41% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
1
Investors (latest)
2024-11-26
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$25M$50M$75M$100MPre-Seed · 2010-12-01 Raised $1.0M (real) Modeled valuation $51M (est)$1.0M$51MPre-Seed2010Pre-Seed · 2014-10-03 Raised $900K (real) Modeled valuation $46M (est)$900K$46MPre-Seed2014Pre-Seed · 2024-11-26 Raised $667K (real) Modeled valuation $2.4M (est)$667K$2.4MPre-Seed2024+$900K+$667KCumulative $2.6M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$1.0M · 2010
Pre-Seed extension$900K · 2014
Pre-Seed extension$667K · 2024

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$2.4M
Base estimate est.
$365K
Conservative case
$7.1M
Upside case
$3.7M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Pre-Seeda round under $1.0M). Valuation is modeled from stage benchmarks scaled by the biotech/pharma sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $51.2M · 2010-12-012010Pre-Seed · modeled $46.0M · 2014-10-03Pre-Seed · modeled $2.4M · 2024-11-262024
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
25%
Survival probability
10% low · 45% high
1.83×/yr
Annual markup
2.48×/yr upside case
1.6 yr
Elapsed time used
1.6 yr actual, capped for stale marks
biotech/pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
84 mo
Avg between rounds
$184K/yr
Capital velocity
15.6 yr
On record since
2010
First round
3
Rounds on file
How it compares to the market

Benchmarked against 227 companies in Biotech / Pharma. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.5× of median
This company$2.6M
Sector median$5.6M
Latest round — vs other Pre-Seed rounds in sector (real $, this stage) 2.1× above median
This company$667K
Sector median$317K
Modeled value — vs sector median (estimate, all stages) 0.1× of median
This company$2.4M
Sector median$30.5M

Raised more than 41% of sector peers (real $). Modeled value above 17% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Pre-Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #13 of 28.

This companyCohort peer
$1.0M$10.0M$100.0M$100K$1.0M$10.0MCapital raised (log)Gaingels Oct Bio LLC · Pre-Seed Raised $552K · modeled $10.6M (est)Gaingels Alto Pharmacy LLC · Pre-Seed Raised $539K · modeled $9.5M (est)Pyros Pharmaceuticals, Inc. · Pre-Seed Raised $880K · modeled $8.2M (est)Allander Biotechnologies, Inc. · Pre-Seed Raised $1.0M · modeled $7.2M (est)CyMon Bio, Inc. · Pre-Seed Raised $922K · modeled $5.4M (est)EOF Bio LLC · Pre-Seed Raised $584K · modeled $4.9M (est)Gaingels Kernal Bio 2022 LLC · Pre-Seed Raised $252K · modeled $4.9M (est)Gaingels Alto Pharmacy 2023 LLC · Pre-Seed Raised $525K · modeled $4.4M (est)Pandora Bio, Inc. · Pre-Seed Raised $410K · modeled $3.7M (est)Gaingels Renewal Bio LLC · Pre-Seed Raised $313K · modeled $3.0M (est)Gaingels BigHat Biosciences LLC · Pre-Seed Raised $164K · modeled $2.5M (est)Penrhos Bio Ltd · Pre-Seed Raised $282K · modeled $2.4M (est)Spinnaker Biosciences, Inc. (this company) Raised $2.6M · modeled $2.4M (est)Spinnaker Biosciences, Inc.
CompanyStageRaised · realValue · estvs peer med.
Gaingels Oct Bio LLCPre-Seed$552K$10.6M5.00×
Gaingels Alto Pharmacy LLCPre-Seed$539K$9.5M4.50×
Pyros Pharmaceuticals, Inc.Pre-Seed$880K$8.2M3.86×
Allander Biotechnologies, Inc.Pre-Seed$1.0M$7.2M3.40×
CyMon Bio, Inc.Pre-Seed$922K$5.4M2.58×
EOF Bio LLCPre-Seed$584K$4.9M2.32×
Gaingels Kernal Bio 2022 LLCPre-Seed$252K$4.9M2.31×
Gaingels Alto Pharmacy 2023 LLCPre-Seed$525K$4.4M2.10×
Pandora Bio, Inc.Pre-Seed$410K$3.7M1.75×
Gaingels Renewal Bio LLCPre-Seed$313K$3.0M1.43×
Gaingels BigHat Biosciences LLCPre-Seed$164K$2.5M1.19×
Penrhos Bio LtdPre-Seed$282K$2.4M1.15×
Spinnaker Biosciences, Inc. this companyPre-Seed$2.6M$2.4M1.13×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$1.0M2010-12-01$5.6M$51.2M85%
Pre-Seed$900K2014-10-03$5.0M$46.0M85%
Pre-Seed$667K2024-11-26$3.7M$2.4M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$1.0M2010-12-01
    • First recorded raise — entered as Pre-Seed.
    • 1 investor on this round.
  2. Pre-Seed$900K2014-10-03
    • Raised again after 46 mo — slower than the ~15 mo sector norm.
    • Round roughly the size of the prior one.
    • Switched to Rule 506(b) (was Rule 06).
    • 2 investors on this round.
  3. Pre-Seed$667K2024-11-26
    • Raised again after 122 mo — slower than the ~15 mo sector norm.
    • Round 1.3× smaller than the prior — bridge or down round.
    • 1 investor on this round.
Intelligence
2031 ~Q4
Modeled next raise · ~84mo cadence
$667K
Modeled next size est.range $667K$1.1M
0.7×
Last step-up
$184K/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Virgil Thompson3 other2010-12
William Freeman1 other2010-12
Malcolm Finlayson2024-11
Michael J. Sailor2010-12
Michael Sailor2014-10
Registry & provenance

Spinnaker Biosciences, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1507786
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
GenZ Corp.ManufacturingPre-Seed$2.6M$6.9Mnetwork1 shared operator · same stage
XOStem Biosciences Ltd.Biotech / PharmaPre-Seed$3.3M$2.2Msame sector · same stage
Me Biosciences, Inc.Biotech / PharmaPre-Seed$1.4M$25.6Msame sector · same stage
Orbis Biosciences, IncBiotech / PharmaPre-Seed$1.2M$50.4Msame sector · same stage
Cosmos Pharmaceuticals, LLCBiotech / PharmaPre-Seed$1.1M$1.6Msame sector · same stage
AbX Biologics, Inc.Biotech / PharmaPre-Seed$1.0M$51.2Msame sector · same stage
Allander Biotechnologies, Inc.Biotech / PharmaPre-Seed$1.0M$7.2Msame sector · same stage
Cage Pharmaceuticals, Inc.Biotech / PharmaPre-Seed$967K$696Ksame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Akers Biosciences, Inc.Biotech / PharmaSeries B$30.5M85%
Bond Biosciences, Inc.Biotech / PharmaSeries A$21.9M85%
Spinogenix, Inc.Other Health CareSeries A$31.0M84%
Teal Bio, Inc.Biotech / PharmaSeed$1.5M84%
Los Angeles Biosciences, Inc.Biotech / PharmaSeries A$16.4M83%
IpiNovyx Bio, Inc.Biotech / PharmaSeries A$131.4M83%
Ensysce Biosciences, Inc.Biotech / PharmaSeries A$7.9M83%
Snider Health, LlcHealthtechSeries A$158.0M83%
Frequently asked
How much funding has Spinnaker Biosciences, Inc. raised?
Spinnaker Biosciences, Inc. has raised approximately $2.6M in disclosed capital across 3 recorded financing rounds, aggregated from public filings.
What is Spinnaker Biosciences, Inc.'s estimated valuation?
Provath's modeled valuation for Spinnaker Biosciences, Inc. is approximately $2.4M (modeled range $365K–$7.1M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Spinnaker Biosciences, Inc. at?
Spinnaker Biosciences, Inc.'s latest modeled financing stage is Pre-Seed. Its most recent recorded round closed around Tue Nov 26.
What does Spinnaker Biosciences, Inc. do and where is it based?
Spinnaker Biosciences, Inc. operates in the Biotech / Pharma sector, based in SOLANA BEACH.
Explore related

See where Spinnaker Biosciences, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Spinnaker Biosciences, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.